Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical, with a price target of $25.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Chico is a 5-star analyst with an average return of 10.9% and a 51.31% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.

In addition to Wedbush, Ultragenyx Pharmaceutical also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued on February 4. However, today, Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (NASDAQ: RARE).

Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.93 million and a GAAP net loss of $180.41 million. In comparison, last year the company earned a revenue of $139.49 million and had a GAAP net loss of $133.52 million

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year. Earlier this month, Howard Horn, the CFO of RARE sold 3,061.00 shares for a total of $72,117.16.